ClinicalTrials.gg
CompletedNCT01231321Updated Apr 26, 2011Results posted

A Study of Adalimumab When Added to Inadequate Standard Anti-rheumatic Therapy in Patients With Active Rheumatoid Arthritis

A Phase 3 interventional study of adalimumab in Rheumatoid Arthritis, sponsored by Abbott. Completed at 5 sites in Russian Federation. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-04-26.

Sponsored by Abbott · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
100
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 87 studies testing adalimumab in Arthritis, Rheumatoid — 4 open to participants now, 6 under way, 2 of them phase 3. Adalimumab · Arthritis, Rheumatoid.

Enrollment
54th of 87
100 · median 160
Started
2007
with 6 others
Phase 3
36 of 87
1 open now
Registered
40th of 87
by date
Lead sponsor
22 of 87
Abbott

Among the 87 studies testing adalimumab in Arthritis, Rheumatoid, this one is the 54th largest by enrollment, is one of 7 that started in 2007, is one of 36 in phase 3, and was the 40th registered.

Arthritis, Rheumatoid

3,336 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

4 of the 87 studies testing adalimumab in Arthritis, Rheumatoid are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About adalimumab

Adalimumab: first FDA approval 2002 (HUMIRA), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 87 studies testing adalimumab in Arthritis, Rheumatoid, or all of them as a file.
02

Study summary

A total of 100 participants diagnosed with active rheumatoid arthritis were enrolled at 5 sites in Russia. Adalimumab was administered by subcutaneous injection every other week, with dose escalation to weekly dosing available for participants not receiving concomitant disease-modifying antirheumatic drugs (DMARDs) who did not achieve American College of Rheumatology 20 (ACR20) criteria after 12 weeks of treatment. Efficacy and safety measurements were performed throughout the study.

Read the detailed description

This is an open-label, multicenter study designed to establish the safety and efficacy of adalimumab in the treatment of moderate to severely active rheumatoid arthritis. A total of 100 subjects with inadequate preexisting standard anti-rheumatic therapy were enrolled at 5 sites in Russia.

03

Conditions studied

  • Rheumatoid Arthritis

Keywords

  • Adalimumab added to inadequate standard anti-rheumatic therapy in patients with active Rheumatoid Arthritis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Males and females >= 18 years of age.
  2. A negative pregnancy test (human chorionic gonadotropin in serum samples) for women of prior to start of study treatment.
  3. Female subject is either not of childbearing potential, defined as (at least 1 year since last menses) or surgically sterile (bilateral tubal ligation, bilateral oophorectomy or hysterectomy), or is of childbearing potential and practicing one of the following methods of throughout the study and for 150 days after study completion:

    • Condoms, sponge, foams, jellies, diaphragm or intrauterine device.
    • Contraceptives (oral, parenteral, patch) for three months prior to study drug administration.
    • A vasectomized partner.
  4. American College of Rheumatology criteria for diagnosis of rheumatoid arthritis for at least 6 months.
  5. Subjects must meet the following three criteria:

    • Disease Activity Score (28 joints) more or equal 3.2 (at Baseline only)
    • At least 6 swollen joints out of the 66 assessed
    • At least 8 tender joints out of the 68 assessed
  6. Subjects must have a C-reactive protein >= 1.5mg/dL or erythrocyte sedimentation rate >= 28 mm/1h.
  7. Unsatisfactory response or intolerance to prior disease modifying anti-rheumatic drugs (must have failed at least 1 disease modifying anti-rheumatic drug).
  8. Able and willing to administer subcutaneous injections.
  9. Able and willing to give written and to comply with the requirements of the study protocol.
  10. Documented negative purified protein derivative test, defined as \< 5 mm induration, or willingness and ability to start tuberculosis prophylaxis before first dose of study drug if the purified protein derivative result is positive and the chest X-ray is not suggestive of active tuberculosis and there is no history of active tuberculosis.

Exclusion criteria

Exclusion Criteria:

  1. Prior treatment with alkylating agents such as cyclophosphamide or chlorambucil within at least 5 years before enrollment.
  2. Prior treatment with intravenous immunoglobulin or any agent "chemical" in nature within 30 days, or 5 half lives of the product, whichever is longer.
  3. Prior treatment with cyclosporine within the last 6 months.
  4. Prior treatment with investigational biologic therapy.
  5. Subject has chronic arthritis diagnosis before the age 17 years.
  6. Subject has undergone joint surgery within the preceding two months (at joints to be assessed within the study).
  7. History of an allergic reaction or significant sensitivity to the constituents of study drug (adalimumab).
  8. Treatment within the last 2 months with approved biologic therapy (e.g. infliximab) prior to Baseline.
  9. Prior treatment with total lymphoid irradiation.
  10. History of cancer or lymphoproliferative disease other than a successfully and completely treated non- cutaneous squamous cell or basal cell carcinoma and/or localized carcinoma in situ of the cervix.
  11. History of or current acute inflammatory joint disease of origin other than rheumatoid arthritis, e.g. mixed connective tissue disease, systemic lupus erythematosus etc.
  12. History of uncontrolled diabetes, unstable ischemic heart disease, congestive heart failure ( III-IV), active peptic ulcer disease, recent stroke (within 3 months) and any other condition which, in the opinion of the investigator, would put the subject at risk by participation in the protocol.
  13. Subject is known to have immune deficiency, history of positive status or is .
  14. Persistent chronic infection, or severe infections requiring hospitalization or treatment with intravenous antibiotics within 30 days, or oral antibiotics within 14 days prior to enrollment.
  15. Female subjects who are pregnant or breast-feeding or is considering becoming pregnant during the study or for 150 days after the last dose of study medication.
  16. History of drug or alcohol abuse in the last year.
  17. Previous diagnosis or signs of central nervous system demyelinating diseases.
  18. History of untreated or active tuberculosis, histoplasmosis or listeriosis.
  19. History of clinically significant hematologic (e.g. severe anemia, leucopenia, thrombocytopenia), renal or liver disease (e.g. fibrosis, cirrhosis, hepatitis).
  20. Screening clinical laboratory analysis showing any of the following abnormal laboratory results:

    • or alanine transaminase > 1.75 x the .
    • Serum total >= 1.5 mg/dL (>= 26 micromol/L).
    • Creatinine > 1.5 mg/dL (133 micromol/L) in subjects \< 65 years old and > upper limit of normal range in subjects >= 65 years old.
    • Positive or C serology indicative of previous or current infections.
  21. Subject is considered by the Investigator, for any reason, to be an unsuitable candidate for the study.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
100 participants (actual)

Study arms

  • Experimental
    adalimumab

    Adalimumab / pre-filled syringe 40 mg/0.8 ml

    Drug: adalimumab

Interventions

  • Adalimumab 40 mg in 0.8 ml in pre-filled syringe for under the skin of the abdomen or the thigh injection every other week.

    Also known as: ABT-D2E7, Humira

06

What researchers measure

Primary outcomes

  1. Frequency of Adverse Events

    Serious adverse events were collected from the time of informed consent, and nonserious adverse events were collected from the time of first dose of adalimumab, until 70 days after the last injection of adalimumab. Refer to the Reported Adverse Events section of this results disclosure for specific adverse events reported. Note: Severe events considerably interfered in patients' usual activities and may have been life-threatening. Serious events were life-threatening; resulted in hospitalization, congenital anomalies, or disability; or required intervention to prevent seriousness.

    Time frame: Up to 34 weeks (24 week study treatment plus 70-day follow-up period)

  2. Changes of Physical Examination

    Physical examination findings were compared between Baseline and Week 24, and changes were recorded (Normal at Baseline to Abnormal at Week 24; or Abnormal at Baseline to Normal at Week 24). Physical examination criteria (normal vs. abnormal) were at the clinical judgement of the examining physician. Significant changes in physical examination from Baseline were considered to be adverse events.

    Time frame: Baseline and 24 weeks

  3. Deviation From Normal Laboratory Ranges

    Laboratory values were assessed for values above and below the normal (reference) ranges used by the central laboratory. Note abbreviations used in table: Alk. phosphatase = alkaline phosphatase, ALT = alanine aminotransferase, AST = aspartate aminotransferase, ESR = erythrocyte sedimentation rate

    Time frame: 24 weeks

  4. Vital Sign Values

    Vital signs values were assessed for values above and below the normal (reference) ranges used by the central laboratory. Note, in table, BP = blood pressure.

    Time frame: 24 weeks

Secondary outcomes

  1. Change in Disease Activity Score (DAS28) Compared With Baseline

    The DAS28 is validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, C-reactive protein, and general health (patient's global assessment of disease activity) were included in the DAS28 score. Scores on the DAS28 range from 1 (inactive disease) to 10 (very active disease).

    Time frame: Baseline and 24 weeks

07

Results

Posted Mar 24, 2011

Participant flow

Participant flow — Overall Study
MilestoneAdalimumab/ Pre-filled Syringe 40 mg/0.8 mL
Started100
Completed95
Not completed5
Withdrew: Adverse event3
Withdrew: Lack of efficacy2

Outcome measures

PrimaryFrequency of Adverse Events

Serious adverse events were collected from the time of informed consent, and nonserious adverse events were collected from the time of first dose of adalimumab, until 70 days after the last injection of adalimumab. Refer to the Reported Adverse Events section of this results disclosure for specific adverse events reported. Note: Severe events considerably interfered in patients' usual activities and may have been life-threatening. Serious events were life-threatening; resulted in hospitalization, congenital anomalies, or disability; or required intervention to prevent seriousness.

Time frame:
Up to 34 weeks (24 week study treatment plus 70-day follow-up period)
Reported as:
Number · participants
Frequency of Adverse Events
participantsAdalimumab/ Pre-filled Syringe 40 mg/0.8 mL
Adverse events38
Serious adverse events1
Severe adverse events1
Possibly or probably related to adalimumab24
Adverse events leading to discontinuation3
Fatal adverse events0
PrimaryChanges of Physical Examination

Physical examination findings were compared between Baseline and Week 24, and changes were recorded (Normal at Baseline to Abnormal at Week 24; or Abnormal at Baseline to Normal at Week 24). Physical examination criteria (normal vs. abnormal) were at the clinical judgement of the examining physician. Significant changes in physical examination from Baseline were considered to be adverse events.

Time frame:
Baseline and 24 weeks
Reported as:
Number · participants
Changes of Physical Examination
participantsChange From Normal to AbnormalChange From Abnormal to Normal
General Appearance00
Head00
Ears00
Eyes10
Nose00
Throat00
Neck00
Thyroid00
Lungs/Chest00
Cardiovascular10
Abdomen00
Musculoskeletal00
Extremities00
Skin01
Lymph nodes11
Neurological00
Genitourinary00
Other00
PrimaryDeviation From Normal Laboratory Ranges

Laboratory values were assessed for values above and below the normal (reference) ranges used by the central laboratory. Note abbreviations used in table: Alk. phosphatase = alkaline phosphatase, ALT = alanine aminotransferase, AST = aspartate aminotransferase, ESR = erythrocyte sedimentation rate

Time frame:
24 weeks
Reported as:
Number · participants
Deviation From Normal Laboratory Ranges
participantsBelow Reference RangeAbove Reference Range
Basophils (%) (ref. range: 0% - 1%) (n = 95)00
Basophils (ref. range 0 - 2 x 10^9/L) (n = 94)00
Eosinophils (%) (ref. range 1% - 5%) (n = 95)1711
Eosinophils (ref. range 0 - 1 x 10^9/L) (n = 94)00
Erythrocytes (ref. range 4 - 5 x 10^12/L) (n = 95)159
ESR (ref. range 0 - 30 mm/h) (n = 75)014
Hematocrit (ref. range 35% - 47%) (n = 95)152
Hemoglobin (ref. range 12 - 16 g/dL) (n = 95)331
Leucocytes (ref. range 4 - 11 x 10^3/L) (n = 95)310
Lymphocytes (%) (ref. range 19% - 37%) (n = 95)1524
Lymphocytes (ref. range 2 - 4 x 10^9/L) (n = 94)446
Monocytes (%) (ref. range 3% - 11%) (n = 95)112
Monocytes (ref. range 0 - 1 x 10^9/L) (n = 94)06
Neutrophils (%) (ref. range 48% - 78%) (n = 95)206
Neutrophils (ref. range 2 - 9 x 10^9/L) (n = 95)53
Platelets (ref. range 150-400 x 10^3/mcL) (n = 95)09
Albumin (ref. range 35 - 50 g/L) (n = 97)014
Alk. phosphatase (ref. range 40-150 U/L) (n = 97)12
ALT (ref. range 0 - 31 U/L) (n = 97)09
AST (ref. range 0 - 31 U/L) (n = 97)06
Calcium (ref. range 2 - 3 mmol/L) (n = 97)10
Chloride (ref. range 98 - 107 mEq/L) (n = 96)00
Creatine kinase (ref. range 0 - 167 U/L) (n = 97)02
Creatinine (ref. range 53 - 97 mcmol/L) (n = 97)11
C-reactive protein (ref. range 0-5 mg/L) (n = 97)045
Glucose (ref. range 4- 6 mmol/L) (n = 97)410
Potassium (ref. range 4 - 6 mmol/L) (n = 97)210
Sodium (ref. range 136 - 145 mmol/L) (n = 97)20
Total bilirubin (ref. range 3-20 mcmol/L) (n = 97)05
Total cholesterol (ref. range 4-8 mmol/L) (n = 97)54
Total protein (ref. range 64-83 g/L) (n = 97)32
Urea (ref. range 2 - 6 mmol/L) (n = 96)030
Urea nitrogen (ref. range 6 - 20 mg/dL) (n = 97)011
Uric acid (ref. range 150 - 350 mcmol/L) (n = 97)116
Urine pH (ref. range 5 - 8) (n = 98)01
PrimaryVital Sign Values

Vital signs values were assessed for values above and below the normal (reference) ranges used by the central laboratory. Note, in table, BP = blood pressure.

Time frame:
24 weeks
Reported as:
Number · participants
Vital Sign Values
participantsBelow Reference RangeAbove Reference Range
Systolic BP (ref. range 100 - 140 mm Hg)12
Diastolic BP (ref. range 60 - 100 mm Hg)00
Pulse (ref. range 50 - 90 beats/min)00
Body temperature (ref. range 36 - 37 degrees C)10
SecondaryChange in Disease Activity Score (DAS28) Compared With Baseline

The DAS28 is validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, C-reactive protein, and general health (patient's global assessment of disease activity) were included in the DAS28 score. Scores on the DAS28 range from 1 (inactive disease) to 10 (very active disease).

Time frame:
Baseline and 24 weeks
Reported as:
Mean · units on a scale
Change in Disease Activity Score (DAS28) Compared With Baseline
units on a scaleAdalimumab/ Pre-filled Syringe 40 mg/0.8 mL
Change in Disease Activity Score (DAS28) Compared With Baseline-2.74 ± 1.18

Adverse events

Collected over Adverse events were collected from the time of informed consent up to 70 days after the last injection of adalimumab.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Adalimumab/ Pre-filled Syringe 40 mg/0.8 mL—1/100 (1%)38/100 (38%)
Most frequent serious events
Most frequent serious events
EventAdalimumab/ Pre-filled Syringe 40 mg/0.8 mL
Pyogenic arthritisInfections and infestations1/100
Most frequent other events
Showing 10 of 44
Most frequent other events
EventAdalimumab/ Pre-filled Syringe 40 mg/0.8 mL
NasopharyngitisInfections and infestations4/100
Respiratory disorderRespiratory, thoracic and mediastinal disorders4/100
HeadacheNervous system disorders3/100
Injection site erythemaGeneral disorders3/100
OsteochondrosisMusculoskeletal and connective tissue disorders3/100
Respiratory tract infection viralInfections and infestations3/100
Rheumatoid arthritisMusculoskeletal and connective tissue disorders3/100
Back painMusculoskeletal and connective tissue disorders2/100
Body temperature increasedInvestigations2/100
Injection site pruritusGeneral disorders2/100

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Adalimumab/ Pre-filled Syringe 40 mg/0.8 mL
<=18 years0
Between 18 and 65 years90
>=65 years10
Age Continuous
Age Continuous(years)Adalimumab/ Pre-filled Syringe 40 mg/0.8 mL
Mean50.9 ± 11.1
Sex: Female, Male
Sex: Female, Male(Participants)Adalimumab/ Pre-filled Syringe 40 mg/0.8 mL
Female89
Male11
Region of Enrollment
Region of Enrollment(participants)Adalimumab/ Pre-filled Syringe 40 mg/0.8 mL
Russian Federation100
08

Study locations

5 sites
  • Site Ref # / Investigator 17682
    Kazan, 420095, Russian Federation
  • Site Ref # / Investigator 7417
    Moscow, 115522, Russian Federation
  • Site Ref # / Investigator 17681
    Moscow, 117513, Russian Federation
  • Site Ref # / Investigator 7401
    Moscow, 119049, Russian Federation
  • Site Ref # / Investigator 18081
    Saint Petersburg, 191015, Russian Federation
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2007, a primary completion of Feb 2010 and a completion of Feb 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2011, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 28, 2010
First posted
Nov 1, 2010
Start
Dec 2007
Primary completionActual
Feb 2010
CompletionActual
Feb 2010
Results first posted
Mar 24, 2011
Last update
Apr 26, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 26, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01231321
Lead sponsor
Abbott
First posted
Nov 1, 2010
Start date
Dec 2007
Primary completion
Feb 2010
Completion
Feb 2010
Results posted
Mar 24, 2011
Last update
Apr 26, 2011

Study contacts

Konstantin Gudkov, MD
study director · Abbott

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Adalimumab

Start the discussion